ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020
Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Relationship of asprosin and diabetes: a meta-analysis.BMC endocrine disorders · 2025Pooled it
- Pooled it
- Serum and gingival crevicular fluid asprosin levels in obese and normal-weight individuals with and without periodontitis: a cross-sectional study.BMC oral health · 2026Article
- The correlation between serum calcium and asprosin in elderly patients with type 2 diabetes mellitus in community.Frontiers in endocrinology · 2026Article
- Asprosin Aggravates Tubular Epithelial Cell Injury and Phenotypic Transformation via Mitochondrial Dynamics Disorder Mediated by Excessive Drp1 SUMOylation in Diabetic Nephropathy Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- The Associations between Asprosine, Clusterin, Zinc Alpha-2-Glycoprotein, Nuclear Factor Kappa B, and Peroxisome Proliferator-Activated Receptor Gamma in the Development of Complications in Type 2 Diabetes Mellitus.Journal of clinical medicine · 2024Article
- Asprosin: its function as a novel endocrine factor in metabolic-related diseases.Journal of endocrinological investigation · 2024Review
- Increased serum asprosin is correlated with diabetes mellitus-induced erectile dysfunction.Diabetology & metabolic syndrome · 2024Article
- Association of serum Asprosin concentrations with heart failure.BMC cardiovascular disorders · 2023Article
- Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model.Korean circulation journal · 2023Article
- Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by theMolecular syndromology · 2022Review
- Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease.Cardiovascular diabetology · 2022Article
- Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects.Frontiers in endocrinology · 2022Review
- The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases.Frontiers in physiology · 2022Review
- Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus in the Community: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Increased serum asprosin is correlated with diabetic nephropathy.Diabetology & metabolic syndrome · 2021Article
- EFFECT OF PIOGLITAZONE TREATMENT ON ASPROSIN LEVELS IN PATIENTS WITH DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MAFLD).Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe detected whether serum asprosin levels play a role in the occurrence and development of albuminuria in patients with type 2 diabetes mellitus (T2DM), which has not been previously discussed.
methodsBased on urinary albumin/creatinine ratio (UACR), 207 T2DM patients were divided into T2DM patients with normoalbuminuria (UACR<30 mg/g), microalbuminuria (30≤UACR<300 mg/g), and macroalbuminuria (UACR≥300 mg/g). Serum asprosin levels were determined by enzyme-linked immunosorbent assay.
resultsComparatively, the serum asprosin levels in T2DM patient groups with macroalbuminuria [2.37 (1.63-3.57)] and microalbuminuria [2.10 (1.60-2.90)] were significantly increased than the normoalbuminuria group [1.59 (1.18-2.09)] (
conclusionObviously, the serum asprosin level was independently correlated with UACR in T2DM patients, which implies circulating asprosin may play an essential role in the pathogenesis of diabetic nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.